IL156873A0 - Pharmaceutically active piperidine derivatives - Google Patents

Pharmaceutically active piperidine derivatives

Info

Publication number
IL156873A0
IL156873A0 IL15687302A IL15687302A IL156873A0 IL 156873 A0 IL156873 A0 IL 156873A0 IL 15687302 A IL15687302 A IL 15687302A IL 15687302 A IL15687302 A IL 15687302A IL 156873 A0 IL156873 A0 IL 156873A0
Authority
IL
Israel
Prior art keywords
pharmaceutically active
piperidine derivatives
active piperidine
derivatives
inhibitors
Prior art date
Application number
IL15687302A
Other languages
English (en)
Original Assignee
Oxford Glycosciences Uk Ltd
Univ Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd, Univ Oxford filed Critical Oxford Glycosciences Uk Ltd
Publication of IL156873A0 publication Critical patent/IL156873A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
IL15687302A 2001-01-12 2002-01-11 Pharmaceutically active piperidine derivatives IL156873A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0100889.5A GB0100889D0 (en) 2001-01-12 2001-01-12 Compounds
PCT/GB2002/000106 WO2002055498A1 (en) 2001-01-12 2002-01-11 Pharmaceutically active piperidine derivatives

Publications (1)

Publication Number Publication Date
IL156873A0 true IL156873A0 (en) 2004-02-08

Family

ID=9906757

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15687302A IL156873A0 (en) 2001-01-12 2002-01-11 Pharmaceutically active piperidine derivatives

Country Status (19)

Country Link
US (3) US20040097551A1 (de)
EP (1) EP1362031B1 (de)
JP (1) JP4313572B2 (de)
KR (1) KR100879651B1 (de)
CN (1) CN1267420C (de)
AT (1) ATE389635T1 (de)
AU (1) AU2002219363B2 (de)
BR (1) BRPI0206433B8 (de)
CA (1) CA2433675C (de)
DE (1) DE60225671T2 (de)
ES (1) ES2304439T3 (de)
GB (1) GB0100889D0 (de)
HU (1) HU229428B1 (de)
IL (1) IL156873A0 (de)
MX (1) MXPA03006185A (de)
PT (1) PT1362031E (de)
RU (1) RU2279425C2 (de)
WO (1) WO2002055498A1 (de)
ZA (1) ZA200305118B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
ES2271548T3 (es) * 2002-03-13 2007-04-16 Unither Pharmaceuticals, Inc. Enfoque no hormonal de anticoncepcion masculina.
AU2003246942B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
EP1554245B1 (de) * 2002-07-17 2012-09-26 Actelion Pharmaceuticals Ltd. Piperidintriolderivate als inhibitoren von glycosylceramidsynthase
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
EP1528056A1 (de) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin Derivate und ihre Verwendung als Glukosesylceramidase-Inhibitoren
EP1680112B1 (de) * 2003-10-29 2010-12-15 Genzyme Corporation N-(5-adamantane-1-yl-methoxy-pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz
GB0400812D0 (en) * 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
WO2005092334A2 (en) * 2004-03-25 2005-10-06 David Priestman Use of n-substituted imino sugars for appetite suppression
US20070248591A1 (en) * 2004-09-08 2007-10-25 Takeda Pharmaceutical Company Limited Preventive/Therapeutic Drug for Arteriosclerosis
EP1811991B1 (de) 2004-11-10 2018-11-07 Genzyme Corporation Behandlung von Typ 2 Diabetes mit Inhibitoren der Glycosphigolipid-Synthese
EP2923699B1 (de) 2006-05-09 2018-06-20 Genzyme Corporation Verfahren zur behandlung von krankhafter fettleber durch hemmung der glucosphingolipid-synthese
US8975280B2 (en) 2006-05-24 2015-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Deoxynojirimycin and D-arabinitol analogs and methods of using
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
EP2594564B1 (de) 2007-05-31 2016-09-28 Genzyme Corporation Glukosylceramid-Synthase-Hemmer vom 2-Acylaminpropanol-Typ
BRPI0817864A2 (pt) 2007-10-05 2012-12-25 Genzyme Corp uso de um composto derivado de ceramida
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010039256A1 (en) * 2008-10-03 2010-04-08 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
EP3608330B1 (de) 2008-12-16 2022-11-09 Genzyme Corporation Synthetische zwischenprodukte zur verwendung zur herstellung von oligosaccharid-protein-konjugate
CA2753195C (en) 2009-02-23 2015-06-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
EP2400843B1 (de) * 2009-02-24 2015-11-11 United Therapeutics Corporation Iminozucker und verfahren zur behandlung von arenaviridae-erkrankungen
EP2440205B1 (de) * 2009-06-12 2014-08-27 United Therapeutics Corporation Iminozucker zur verwendung in der behandlung von bunyaviralen und togaviralen erkrankungen
BR112012004676A2 (pt) * 2009-09-04 2019-09-24 United Therapeutics Corp método de tratar infecções orotomixovirais.
CN105748476A (zh) * 2009-09-04 2016-07-13 联合治疗公司 亚氨基糖以及治疗丝状病毒性疾病的方法
WO2011028781A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Methods of treating poxviral infections
EP2509598A1 (de) * 2009-12-07 2012-10-17 The Chancellor, Masters And Scholars Of The University Of Oxford N-substituierte deoxynojirimycinverbindungen zur hemmung von osteoklastogenese und/oder oesteoklastenaktivierung
ES2371398B1 (es) * 2010-06-04 2013-05-20 Bioglane, S.L.N.E. Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales.
EP2394667A1 (de) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vektoren und Sequenzen zur Behandlung von Erkrankungen
US20140350049A1 (en) 2011-11-29 2014-11-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of darier disease
JP2016513729A (ja) 2013-03-15 2016-05-16 ユニザー ヴィロロジー，エルエルシー 抗菌化合物
JP2016517887A (ja) * 2013-05-02 2016-06-20 ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード イミノ糖を使用した糖脂質阻害
MX2019014427A (es) 2017-06-01 2020-02-05 Idorsia Pharmaceuticals Ltd Forma cristalina de n-butildeoxigalactonojirimicina.
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
EP3966199A4 (de) * 2019-05-10 2023-02-01 Alectos Therapeutics Inc. Nichtlysosomale glucosylceramidase-inhibitoren und verwendungen davon
AU2021269232A1 (en) * 2020-05-07 2022-12-08 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
PE20231423A1 (es) * 2020-05-07 2023-09-13 Alectos Therapeutics Inc Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos
EP4201403A1 (de) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Verbindungen tirapazamin und quazinon zur verwendung bei der behandlung von gm2-gangliosidosen

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
JPH02306962A (ja) 1989-05-19 1990-12-20 Meiji Seika Kaisha Ltd 新規ｎ―置換―１―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤
JPH0324057A (ja) 1989-06-22 1991-02-01 Tosoh Corp ポリヒドロキシピペリジン類及びその製造法
CA2065446A1 (en) 1989-09-07 1991-03-08 Yoshiaki Yoshikuni Antiviral drug
EP0536402A4 (en) 1990-06-29 1993-05-12 Nippon Shinyaku Company, Limited Piperidine derivative
US5276120A (en) * 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
ATE318910T1 (de) 1993-05-05 2006-03-15 Roche Diagnostics Gmbh Cholesterinoxidase aus brevibacterium sterolicum
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
DE69735669T2 (de) * 1996-07-15 2007-03-29 Macrozyme Dnm B.V. Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
HUP0003362A3 (en) * 1997-05-06 2001-04-28 Novo Nordisk As Piperidine derivatives and pharmaceutical compositions containing them
WO1999001555A1 (en) * 1997-07-03 1999-01-14 The United States Of America Represented By The Secretary, Department Of Health And Human Services Genes for niemann-pick type c disease
JP2001522833A (ja) * 1997-11-10 2001-11-20 ジー・ディー・サール・アンド・カンパニー 多剤耐性を治療するためのアルキル化イミノ糖類の使用
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
WO2000056334A1 (en) 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
AU6050600A (en) * 1999-07-26 2001-02-13 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
DE60037664T2 (de) * 1999-08-10 2008-12-24 The Chancellor, Masters And Scholars Of The University Of Oxford Langkettige n-alkyl verbindungen und deren oxa-derivate zur verwendung als anitvirale mittel
ES2271548T3 (es) * 2002-03-13 2007-04-16 Unither Pharmaceuticals, Inc. Enfoque no hormonal de anticoncepcion masculina.
AU2003246942B2 (en) * 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
EP1554245B1 (de) 2002-07-17 2012-09-26 Actelion Pharmaceuticals Ltd. Piperidintriolderivate als inhibitoren von glycosylceramidsynthase
GB0313677D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds

Also Published As

Publication number Publication date
ZA200305118B (en) 2004-10-01
CN1496351A (zh) 2004-05-12
BRPI0206433B8 (pt) 2021-05-25
RU2279425C2 (ru) 2006-07-10
DE60225671T2 (de) 2009-04-16
KR20030081383A (ko) 2003-10-17
JP4313572B2 (ja) 2009-08-12
CA2433675C (en) 2011-03-22
CA2433675A1 (en) 2002-07-18
EP1362031B1 (de) 2008-03-19
HUP0303891A3 (en) 2010-01-28
AU2002219363B2 (en) 2007-11-01
US20040097551A1 (en) 2004-05-20
US20060074107A1 (en) 2006-04-06
ES2304439T3 (es) 2008-10-16
PT1362031E (pt) 2008-06-12
US8729099B2 (en) 2014-05-20
BR0206433A (pt) 2003-12-30
EP1362031A1 (de) 2003-11-19
US9199935B2 (en) 2015-12-01
RU2003124756A (ru) 2005-01-10
MXPA03006185A (es) 2004-12-03
WO2002055498A1 (en) 2002-07-18
ATE389635T1 (de) 2008-04-15
GB0100889D0 (en) 2001-02-21
BRPI0206433B1 (pt) 2020-01-07
HU229428B1 (en) 2013-12-30
HUP0303891A2 (hu) 2004-03-29
US20140303208A1 (en) 2014-10-09
DE60225671D1 (de) 2008-04-30
JP2004517869A (ja) 2004-06-17
CN1267420C (zh) 2006-08-02
KR100879651B1 (ko) 2009-01-20

Similar Documents

Publication Publication Date Title
IL156873A0 (en) Pharmaceutically active piperidine derivatives
DK1206467T3 (da) N-heterocykliske derivater som NOS-inhibitorer
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
SE0202463D0 (sv) Novel compounds
NO20031001L (no) Polyarylkarboksamider nyttige som lipidsenkende midler
DK1268471T3 (da) N-heterocykliske derivater som NOS-inhibitorer
NO20066055L (no) Pyridinderivater
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
SE0400284D0 (sv) Novel compounds
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
ATE353216T1 (de) 1-substituierten imidazol derivaten als nos inhibitoren
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
NO20054787D0 (no) Indenderivater som farmasotiske midler
SE0103710D0 (sv) Compounds
NO20052182L (no) Nye forbindelser
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
TR200001452T2 (tr) Bifenilamidin türevleri.
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
BRPI0415390A (pt) compostos de pirazinona substituìda para o tratamento da inflamação
GB0308201D0 (en) Novel compounds
NO20062307L (no) Spirofuropyridinarylderivater
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed